MX2016005488A - Vector hsv oncolitico. - Google Patents

Vector hsv oncolitico.

Info

Publication number
MX2016005488A
MX2016005488A MX2016005488A MX2016005488A MX2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A
Authority
MX
Mexico
Prior art keywords
hsv
ohsv
oncolitico
present
inventive
Prior art date
Application number
MX2016005488A
Other languages
English (en)
Other versions
MX379501B (es
Inventor
Uchida Hiroaki
COHEN Justus
C Glorioso Joseph Iii
Grandi Paola
Original Assignee
Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of MX2016005488A publication Critical patent/MX2016005488A/es
Publication of MX379501B publication Critical patent/MX379501B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un Virus oncolítico del Herpes Simple recombinante (oHSV) que comprende un ligante no-HSV específico para una molécula (proteína, lípido, o determinante de carbohidratos) presentes en la superficie de una célula (tal como una célula de cáncer) y una o más copias de una o más secuencias diana de microARN insertadas en uno o más loci de genes HSV, preferiblemente uno o más gen(es) HSV necesario para la replicación de HSV en las células normales (es decir, no cancerosas). La invención proporciona además las acciones y composiciones farmacéuticas que comprenden el oHSV inventivo y métodos para matar las células tumorales que emplean el oHSV inventivo.
MX2016005488A 2013-10-28 2014-10-28 Vector hsv oncolítico. MX379501B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896497P 2013-10-28 2013-10-28
PCT/US2014/062676 WO2015066042A1 (en) 2013-10-28 2014-10-28 Oncolytic hsv vector

Publications (2)

Publication Number Publication Date
MX2016005488A true MX2016005488A (es) 2016-10-03
MX379501B MX379501B (es) 2025-03-11

Family

ID=53005031

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005488A MX379501B (es) 2013-10-28 2014-10-28 Vector hsv oncolítico.
MX2021001158A MX2021001158A (es) 2013-10-28 2016-04-27 Vector hsv oncolitico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001158A MX2021001158A (es) 2013-10-28 2016-04-27 Vector hsv oncolitico.

Country Status (17)

Country Link
US (5) US10201575B2 (es)
EP (3) EP3184641B1 (es)
JP (3) JP6588024B2 (es)
KR (2) KR102490462B1 (es)
CN (2) CN106068326B (es)
AU (1) AU2014342465B2 (es)
BR (1) BR112016009465A8 (es)
CA (1) CA2928956A1 (es)
DK (1) DK3184641T3 (es)
ES (2) ES2781852T3 (es)
IL (2) IL245312B (es)
MX (2) MX379501B (es)
NZ (1) NZ720021A (es)
PT (1) PT3184641T (es)
RU (1) RU2719190C2 (es)
SG (1) SG11201603119RA (es)
WO (1) WO2015066042A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
KR102490462B1 (ko) 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터
PT3256570T (pt) * 2015-02-11 2021-06-18 Univ Bologna Alma Mater Studiorum Herpesvírus redirecionado com fusão de glicoproteína h
WO2017118866A1 (en) 2016-01-08 2017-07-13 Replimune Limited Engineered virus
ES2919953T3 (es) * 2016-01-27 2022-07-29 Oncorus Inc Vectores víricos oncolíticos y usos de los mismos
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
CN108884460B (zh) * 2016-03-19 2023-04-28 埃克苏马生物技术公司 淋巴细胞转导及其扩增调节的方法与组合物
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
SI3377637T1 (sl) * 2016-04-08 2020-08-31 Krystal Biotech, Inc. Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
RU2751236C2 (ru) * 2016-04-22 2021-07-12 Иммвира Ко., Лимитед КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
ES2904882T3 (es) * 2016-04-29 2022-04-06 Virogin Biotech Canada Ltd Vectores de HSV con replicación mejorada en células cancerosas
JP7185278B2 (ja) 2016-06-09 2022-12-07 アルマ・マテール・ストゥディオルム・ウニベルシータ・ディ・ボローニャ 改変糖タンパク質ｂを有するヘルペスウイルス
AU2017276727B2 (en) 2016-06-09 2023-10-05 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein H for propagation in a cell
EP3469071B1 (en) 2016-06-09 2020-12-02 Alma Mater Studiorum -Universita' di Bologna Herpesvirus with modified glycoprotein d
WO2017218689A1 (en) 2016-06-14 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
AU2017292936C1 (en) * 2016-07-08 2024-05-02 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
KR102780496B1 (ko) * 2016-07-29 2025-03-11 오하이오 스테이트 이노베이션 파운데이션 종양용해성 바이러스에 의한 PTEN-Long의 발현
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
AU2018215558B2 (en) * 2017-02-03 2023-05-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
US11680248B2 (en) * 2017-03-09 2023-06-20 Xiamen University Recombinant herpes simplex virus and use thereof
RU2771110C2 (ru) * 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
EP3833765B1 (en) * 2017-08-09 2026-01-14 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
WO2019158955A1 (en) * 2018-02-19 2019-08-22 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
EP3710018A4 (en) * 2017-11-16 2022-03-09 Virogin Biotech Canada Ltd ONCOLYTIC VIRUSES DECORATED BY A TARGETING FRACTION
EP3731850A4 (en) * 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EP3781188A4 (en) * 2018-04-13 2022-03-02 2seventy bio, Inc. ADOPTIVE CELL THERAPY
CN112041434A (zh) 2018-04-27 2020-12-04 克里斯托生物技术股份有限公司 用于美容性应用的编码一种或多种美容蛋白的重组核酸
US12414973B2 (en) 2018-05-31 2025-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Antigenically stealthed oncolytic viruses
KR101998793B1 (ko) * 2018-09-04 2019-07-10 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스의 제조를 위한 벡터
CN111117973A (zh) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 一种受microRNA调控的重组溶瘤肠道病毒71型及应用
MX2021008832A (es) 2019-02-08 2021-09-08 Krystal Biotech Inc Composiciones y metodos para la administracion de polipeptidos cftr.
US12480097B2 (en) * 2019-03-14 2025-11-25 Research Institute At Nationwide Children's Hospital Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics
JP2022536474A (ja) * 2019-06-10 2022-08-17 アクセス ツー アドバンスト ヘルス インスティチュート アストロウイルスレプリコンの方法および組成物
EP4041902A1 (en) 2019-10-10 2022-08-17 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
AU2020374942A1 (en) * 2019-11-01 2022-05-26 University Of Houston System Oncolytic virotherapy with induced anti-tumor immunity
WO2021246815A1 (ko) * 2020-06-03 2021-12-09 주식회사 젠셀메드 Hvec의 세포외 도메인과 암세포 표적화 영역의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
CN115803432A (zh) * 2020-06-12 2023-03-14 吉赛尔美德公司 用于重靶向的具有经修饰的糖蛋白gH的重组单纯疱疹病毒及其用途
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
AU2022246917A1 (en) 2021-04-02 2023-10-12 Krystal Biotech, Inc. Viral vectors for cancer therapy
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
WO2023147566A1 (en) * 2022-01-29 2023-08-03 Virogin Biotech Canada Ltd Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
WO2024151990A1 (en) * 2023-01-13 2024-07-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Effective oncolytic herpes simplex virus vector retargeting
WO2024182737A1 (en) * 2023-03-01 2024-09-06 The Brigham And Women’S Hospital, Inc. Oncolytic viruses to treat brain cancer
CN117085049A (zh) * 2023-08-18 2023-11-21 复旦大学附属中山医院 溶瘤单疱病毒oHSV联合BET抑制剂JQ1在治疗恶性胶质瘤中的应用
WO2025212872A1 (en) * 2024-04-03 2025-10-09 University Of Southern California T-bet induces tumor cell apoptosis and its utility in cancer therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
WO1999006583A1 (en) 1997-07-31 1999-02-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
DE69831754T2 (de) 1997-12-17 2006-06-29 Immunex Corp., Thousand Oaks Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
ES2366608T3 (es) * 2001-03-27 2011-10-21 The General Hospital Corporation Vectores víricos y su uso en métodos terapéuticos.
ATE434624T1 (de) 2001-10-04 2009-07-15 Immunex Corp Ul16-bindungsprotein 4
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
AU2003216502B2 (en) 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
AU2005302408B2 (en) 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
ES2564823T3 (es) 2005-05-27 2016-03-29 Ospedale San Raffaele S.R.L. Vector génico que comprende miARN
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
CA2687301C (en) 2007-05-09 2016-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) * 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
NO2700405T3 (es) * 2008-05-29 2018-09-01
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
US8569065B2 (en) 2009-03-13 2013-10-29 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
CA2795695A1 (en) 2010-04-09 2011-10-13 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
RU2020105656A (ru) 2013-07-17 2021-01-27 Юниверсити Оф Питтсбург- Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Нетоксичные векторы на основе впг для применений в эффективной доставке генов и комплементирующие клетки для их продуцирования
KR102490462B1 (ko) 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Also Published As

Publication number Publication date
CN106068326A (zh) 2016-11-02
SG11201603119RA (en) 2016-05-30
US10576115B2 (en) 2020-03-03
CN113717952A (zh) 2021-11-30
IL245312B (en) 2020-02-27
RU2719190C2 (ru) 2020-04-17
BR112016009465A2 (pt) 2017-10-03
EP3063279B1 (en) 2020-01-01
EP3184641B1 (en) 2020-07-08
JP6588024B2 (ja) 2019-10-09
AU2014342465A1 (en) 2016-06-02
WO2015066042A1 (en) 2015-05-07
KR102330183B1 (ko) 2021-11-23
US20210138007A1 (en) 2021-05-13
US20190262410A1 (en) 2019-08-29
KR20160108301A (ko) 2016-09-19
JP7262134B2 (ja) 2023-04-21
IL272480A (en) 2020-03-31
NZ720021A (en) 2022-08-26
MX379501B (es) 2025-03-11
US20170035819A1 (en) 2017-02-09
IL245312A0 (en) 2016-06-30
IL272480B (en) 2021-06-30
JP6919912B2 (ja) 2021-08-18
BR112016009465A8 (pt) 2018-01-30
EP3063279A4 (en) 2017-05-17
US11883448B2 (en) 2024-01-30
KR102490462B1 (ko) 2023-01-19
ES2781852T3 (es) 2020-09-08
JP2016537020A (ja) 2016-12-01
US10172893B2 (en) 2019-01-08
RU2016120618A3 (es) 2018-05-22
PT3184641T (pt) 2020-08-21
JP2021180661A (ja) 2021-11-25
US20160250267A1 (en) 2016-09-01
CA2928956A1 (en) 2015-05-07
AU2014342465B2 (en) 2018-03-08
US10188686B2 (en) 2019-01-29
ES2810800T3 (es) 2021-03-09
EP3063279A1 (en) 2016-09-07
HK1225756A1 (en) 2017-09-15
CN106068326B (zh) 2021-06-18
EP3778906B1 (en) 2025-07-02
RU2016120618A (ru) 2017-12-06
DK3184641T3 (da) 2020-08-03
EP3778906A1 (en) 2021-02-17
KR20210145296A (ko) 2021-12-01
US20170274025A1 (en) 2017-09-28
MX2021001158A (es) 2021-04-28
US10201575B2 (en) 2019-02-12
JP2020058341A (ja) 2020-04-16
EP3184641A1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
MX2021001158A (es) Vector hsv oncolitico.
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
MX390848B (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
CY1121591T1 (el) Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CO2020007046A2 (es) Plataformas de entrega crispr objetivo
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
AR080009A1 (es) Alteracion genomica objetivo utilizando nucleasas de dedos de zinc
MX373460B (es) Metodo para generar celulas t compatibles para el trasplante alogenico.
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
CR20170406A (es) Arni variante
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
NZ738689A (en) Engineered crispr-cas9 compositions and methods of use
MX2019014100A (es) Variantes de endonucleasas cblb, composiciones y metodos de uso.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
MX2021008464A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2016001044A (es) Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos.
BR112018015390A2 (pt) vetores virais oncolíticos e usos dos mesmos
MX2017008504A (es) Vacuna para enfermedad de newcastle y de bursitis infecciosa (nd-ibd) en vector de hvt mejorada.
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
MX2018003757A (es) Composiciones y metodos para producir celulas dendriticas.